Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289–97.

Article  PubMed  Google Scholar 

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599–613.

Article  CAS  PubMed  Google Scholar 

Khan FA, Khan RA, Iqbal M, Hussain S, Anaesth. Pain Intensive Care. 2012;16(1):92–8.

Google Scholar 

Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.

Article  CAS  PubMed  Google Scholar 

Harrison CN, Barbui T, Bose P, Kiladjian JJ, Mascarenhas J, McMullin MF, et al. Polycythaemia vera. Nat Rev Dis Primers. 2025;11(1):26.

Article  PubMed  Google Scholar 

Barbui T, Carobbio A, Elisa Rumiet E, et al. In contemporary patients with polycythemia vera, rate of thrombosis is lower than historically reported. Blood. 2014;124(19):3021–3.

Article  PubMed  Google Scholar 

Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–9.

Article  PubMed  PubMed Central  Google Scholar 

Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5(11):e366.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35(12):3339–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–61.

Article  PubMed  Google Scholar 

Marchetti M, Maria A, Vannucchi, et al. Appropriate management of polycythaemia Vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):e301–11.

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms, version 1.2025. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477

Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24.

Article  CAS  PubMed  Google Scholar 

Randrianarisoa RMF, Ramanandafy H, Mania A, Monjanel H, Trouillier S. Prevalence and diagnostic performance of iron deficiency in polycythemia. Hematology. 2023. https://doi.org/10.1080/16078454.2023.2204621.

Article  PubMed  Google Scholar 

Kuykendall AT, Fine JT, Kremyanskaya M. Contemporary challenges in polycythemia vera management from the perspective of patients and physicians. Clin Lymphoma Myeloma Leuk. 2024;24(8):512–22.

Article  PubMed  Google Scholar 

Triguero A, Pedraza A, Pérez-Encinas M, et al. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish registry of polycythemia vera. Ann Hematol. 2022;101(10):2231–9.

Article  PubMed  PubMed Central  Google Scholar 

Landolfi R, Di Gennaro L, Barbui T, European collaboration on Low-Dose aspirin in polycythemia Vera (ECLAP), et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446–52.

Article  CAS  PubMed  Google Scholar 

De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010;85(2):97–100.

Article  PubMed  Google Scholar 

Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354–8.

Article  PubMed  Google Scholar 

Gerds T, Mesa A, Burke RM. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analyses from the REVEAL study. Blood. 2024;143(16):1646–55.

Article  CAS  PubMed  Google Scholar 

Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29(3 Suppl 10):16–21.

Article  PubMed  Google Scholar 

Palandri F, Branzanti F, Venturi M, et al. Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes. Ann Hematol. 2024;103:2347–54.

Article  PubMed  PubMed Central  Google Scholar 

Mascarenhas J, Kosiorek E, Prchal H. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139(19):2931–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia Vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–208.

Article  PubMed  Google Scholar 

Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knudsen TA, Skov V, Stevenson K, et al. Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses. Blood Adv. 2022;6(7):2107–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cantisani C, Kiss N, Naqeshbandi AF, et al. Nonmelanoma skin cancer associated with hydroxyurea treatment: overview of the literature and our own experience. Dermatol Ther. 2019;32(5):e13043.

Article  PubMed  Google Scholar 

Ferrari A, Carobbio A, Masciulli A, et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica. 2019;104:2391–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907–13.

Article  PubMed  Google Scholar 

Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410–5.

Article  PubMed  PubMed Central  Google Scholar 

Qin A. An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Front Oncol. 2023;13:1173467.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin XQ, Tao N, Dergay A, et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA. 1998;95(24):14411–6.